

NEXVIAZYME™ INFUSION ORDER

(avalglucosidase alfa)

1 PATIENT INFORMATION

Patient Name: _____ DOB: _____
 Primary Phone: _____ Gender: Male Female
 Address: _____
 City, State, Zip: _____
 Allergy: _____
 Patient Weight: _____ Lbs _____ Kg Date Weighed: _____
 Venous Access Peripheral IV Port _____ G _____ Inch needle
 Device: PIV for port access complications

2 PRESCRIBER INFORMATION

Prescriber's Name: _____
 Contact Person: _____ Phone: _____
 NPI #: _____
 Address: _____
 Address: _____
 City, State, Zip: _____
 Phone: _____ Fax: _____
 Diagnosis: _____ *271.0 Glucogenosis / E74.02 Pompe disease*

3 CATHETER ACCESS AND FLUSH PROTOCOL

ACCESS TYPE	CATHETER FLUSH ORDERS	CATHETER FLUSH PROTOCOL
Peripheral PORT <i>(Also include Peripheral IV for Port Malfunction)</i>	<input type="checkbox"/> 0.9% Saline Flush: Dispense: 30 Days Refills: x 1yr OR _____ Refills Flush line/port with 10mL for patency/SASH protocol. <input type="checkbox"/> Heparin Flush: Dispense: 30 Days Refills: x 1yr OR _____ Refills Flush port with _____ mL of Heparin _____ units/mL per SASH protocol.	CathFlo: 2 mg/2 mL as directed. <i>Pharmacy authorized to dispense upon home health nurse validated port occlusion.</i> <input type="checkbox"/> Dispense: 1 Kit Refills: x 1yr OR _____ Refills

4 PRE-MEDICATION Premedication for administration 30-60 min. prior to drug infusion:

Antipyretic: _____ q.s. 1 month **Refill:** x 1yr OR _____ Refills Not Needed
 Antihistamine: _____ q.s. 1 month **Refill:** x 1yr OR _____ Refills Not Needed
 LMX 4 or (EMLA) Lidocaine 2.5%/Prilocaine 2.5% cream - Apply topically 1 hour prior to starting IV or accessing port **QTY:** 1 **Refill:** x 1yr OR _____ Refills

5 TREATMENT REGIMEN

DOSE	PRESCRIPTION
20 mg/kg (Patient Wt. ≥ 30 kg) 40 mg/kg (Patient Wt. < 30 kg)	Nexviazyme _____ mg IV every _____ weeks _____ vials/infusion Dispense 28 days Refill: 12 Months <i>Round up to the next whole vial (100 mg/10 mL)</i>

INFUSION RATE FOR 1ST AND SUBSEQUENT INFUSIONS (20 MG/KG OR 40 MG/KG)

- Add final reconstituted drug volume to appropriate volume of Dextrose 5% to reach Total Infusion Volume in table below
- Infuse via infusion pump according to rates in the table below through 0.2µ or 0.22µ low protein binding in-line filter
- Start infusion at rate of 1mg/kg/hr (Step 1). If there are no signs of Infusion Associated Reactions (IARs), gradually increase the infusion rate every 30 minutes

Total Infusion Volume (mL)	STEP 1: 1 mg/kg/hr (mL/hr)	STEP 2: 3 mg/kg/hr (mL/hr)	STEP 3: 5 mg/kg/hr (mL/hr)	STEP 4: 7 mg/kg/hr (mL/hr)
_____	_____	_____	_____	_____

OPTIONAL INFUSION RATE FOR SUBSEQUENT INFUSIONS (40MG/KG ONLY)

- The infusion process for doses of 40mg/kg may use either the above 4-step process or the 5-step process below

Total Infusion Volume (mL)	STEP 1: 1 mg/kg/hr (mL/hr)	STEP 2: 3 mg/kg/hr (mL/hr)	STEP 3: 6 mg/kg/hr (mL/hr)	STEP 4: 8 mg/kg/hr (mL/hr)	STEP 5: 10 mg/kg/hr (mL/hr)
_____	_____	_____	_____	_____	_____

SKILLED NURSING VISIT

As needed for IV access, administration, and proper clinical monitoring Administration procedures to be followed per pharmacy protocol

Post Infusion: Flush IV with 25 mL Dextrose 5% at final rate of drug infusion
Vital Signs: At baseline, each rate change, then every _____ minutes during infusion, at completion of post infusion flush and 30 minutes after completion of post infusion flush

Supplies: Provide infusion pump if needed, IV Pole, back-up peripheral IV kit and all necessary infusion supplies.

ALSO SEE PAGE 2 ("NEXVIAZYME INFUSION REACTION MANAGEMENT ORDERS")

6 PROVIDER SIGNATURE ("Nexviazyme™ Infusion Reaction Management Orders")

_____ Date of Signature _____ Date of Signature
 Product Substitution Permitted Signature Dispense as Written Signature

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by the express authority of the sender to the named addressee.

INFUSION REACTION MANAGEMENT ORDERS

Patient Name: _____ DOB: _____

7 EMERGENCY MEDICATIONS - #q.s. Refill: x 1yr OR ____ Refills

- Diphenhydramine 50 mg/mL _____ mg IV if Infusion Reaction
- Epinephrine 2-Pak 0.3 mg injector IM once for severe brochospasm/anaphylaxis and call 911
- Epinephrine 2-Pak 0.15 mg injector - IM once for severe brochospasm/anaphylaxis and call 911
- Corticosteroid: _____
- 0.9% Saline 250 mL - administer at 50 mL/hr once Nexviazyme infusion stops:
- Supplies:** Provide infusion pump if needed, IV Pole, back-up peripheral IV kit and all necessary infusion supplies.

EXAMPLES OF COMPLEX THERAPY INFUSION REACTIONS

- | | | | |
|-----------------|-------------------|------------------|------------------------|
| • Fever | • Rash/Itching | • Abdominal Pain | • Dyspnea |
| • Chills/Rigors | • Swelling/Edema | • Irritability | • Respiratory Distress |
| • Headache | • Nausea/Vomiting | • Hypotension | |

INSTRUCTIONS DURING REACTION

- 1) **STOP NEXVIAZYME™**, flush with 10 mL D5W, and start 0.9% normal saline at 50 mL/hr.
- 2) **ADMINISTER EMERGENCY MEDS FROM BOX 7 ACCORDING TO PHYSICIAN ORDERS**
 - For severe anaphylaxis, administer appropriate Epinephrine Autoinjector IM - may repeat in 20 minutes if needed. Call 911.
- 3) **CALL PHYSICIAN**

8 PROVIDER SIGNATURE

_____ _____
 Product Substitution Permitted Signature Date of Signature Dispense as Written Signature Date of Signature

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by the express authority of the sender to the named addressee.